TCBP Announces First Patient Completed The Full Dose Regimen In ACHIEVE Clinical Trial
Portfolio Pulse from Benzinga Newsdesk
TC BioPharm (NASDAQ:TCBP) announced that the first patient has completed the full dose regimen in the ACHIEVE Phase 2b trial with no adverse events related to TCB008. This milestone in the UK trial involves patients receiving up to four doses of TCB008, with the first patient receiving approximately one billion cells.
September 12, 2024 | 12:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
TC BioPharm's announcement of the first patient completing the full dose regimen in the ACHIEVE Phase 2b trial without adverse events is a positive development. This milestone could boost investor confidence in TCBP's TCB008 therapy.
The completion of the full dose regimen without adverse events is a significant milestone in the clinical trial process, indicating potential safety and efficacy of TCB008. This can positively influence investor sentiment and potentially lead to a short-term increase in TCBP's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100